-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma

Sponsor: Bristol Myers Squibb and Seagen
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Friday, December 8, 2023: 7:00 PM-10:00 PM
Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Alex F. Herrera, MD, City of Hope
Herrera: BMS: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding; Genentech/Roche: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Kite, a Gilead Company: Research Funding; AstraZeneca/MedImmune: Consultancy; Karyopharm Therapeutics: Consultancy; ADC Therapeutics: Consultancy, Research Funding; Takeda: Consultancy; Tubulis GmbH: Consultancy; Regeneron: Consultancy; Genmab: Consultancy; Pfizer: Consultancy; Caribou Biosciences: Consultancy; Adicet Bio: Consultancy; AbbVie: Consultancy; Allogene Therapeutics: Consultancy; Seattle Genetics: Consultancy, Research Funding; Gilead Sciences: Research Funding; AstraZeneca: Research Funding.
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute and Carla Casulo, MD, University of Rochester
Armand: Merck: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; ADC Therapeutics: Consultancy; GenMab: Consultancy; Enterome: Consultancy; Genentech/Roche: Consultancy, Research Funding; ATB Therapeutics: Consultancy; Foresight Diagnostics: Consultancy; Kite - a Gilead company: Research Funding; Adaptive Biotechnologies: Research Funding; IGM: Research Funding; AstraZeneca: Consultancy, Research Funding; MSD: Consultancy, Research Funding; Tessa Therapeutics: Consultancy; Regeneron: Consultancy; Xencor: Consultancy; Affimed Therapeutics: Research Funding. Casulo: Genentech: Consultancy, Research Funding; GenMab: Research Funding; Gilead Sciences: Research Funding; SecuraBio: Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Verastem: Research Funding; Abbvie: Consultancy; Follicular Lymphoma Foundation: Other: Leadership role; Lymphoma Research Foundation: Other: Leadership Role.
On Demand program will be available here January 8, 2024.

This 90-minute symposium will feature 3 experts in treating HL and is designed to highlight recent clinical trial data in cHL, real-world outcomes, and provide patient case examples on how to translate these data into clinical practice. Panel discussion and audience polling questions will be interwoven throughout the program to enhance dialogue.